Fintel will become HC Wainwright & Co. on April 14, 2023.
maintained
Arcadia Biosciences (NASDAQ:RKDA) coverage buy recommendation.
Analyst Price Forecast Suggests 970.46% Up
Average 1 year as of April 6, 2023 price target $71.40 for Arcadia Biosciences. Predictions range from as low as $20.20 to as high as $126.00. The average price target represents a 970.46% increase from the latest reported closing price of $6.67.
see us corporate leaderboard Maximum price target upwards.
Arcadia Biosciences has projected annual revenue of $12 million, an increase of 20.89%. Projected annual non-GAAP EPS
-$0.65.
What are other shareholders doing?
vitalstone financial
You own 0,000 shares representing 0.00% ownership of the company.
Geode Capital Management
It holds 177,000 shares representing a 20.70% ownership interest in the company. In previous filings, the company reported that it owned 178,000 of his shares.
Decrease
0.29%.office
decreased
Portfolio allocation at RKDA increased by 52.25% last quarter.
state street
It holds 102K shares representing 11.87% ownership of the company. No change from the previous quarter.
Harbor Investments
You own 0,000 shares representing 0.00% ownership of the company. No change from the previous quarter.
FNCMX – Fidelity Nasdaq Composite Index Fund
It holds 4K shares representing a 0.43% ownership interest in the company. No change from the previous quarter.
What is Fund Sentiment?
there is 38 funds or institutions reporting positions at Arcadia Biosciences. That’s an increase of his three owners or 8.57% in the last quarter.Portfolio average weight of all funds RKDA exclusive is 0.00%, a decrease of 50.36%. The total number of shares owned by the institution decreased by 27.89% to 2,370,000 shares over the past three months.
of put/call ratio has an RKDA of 0.00, indicating a bullish outlook.
Arcadia Bioscience Background Information
(This description is provided by the company.)
Arcadia Biosciences is a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients. The company’s GoodWheat™ brand of ingredients deliver health benefits to consumers and enable consumer goods companies to differentiate their brands in the marketplace. The company’s GoodHemp™ seed catalog offers genetically superior hemp seeds, explants and extracts, and applies the company’s proprietary crop innovation technology, ArcaTech™, to new crops.
See all Arcadia Biosciences Submissions to regulatory authorities.
This story was originally Fintel.
The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Nasdaq, Inc.
Summarize this content to 100 words
Fintel will become HC Wainwright & Co. on April 14, 2023.
maintained
Arcadia Biosciences (NASDAQ:RKDA) coverage buy recommendation.
Analyst Price Forecast Suggests 970.46% Up
Average 1 year as of April 6, 2023 price target $71.40 for Arcadia Biosciences. Predictions range from as low as $20.20 to as high as $126.00. The average price target represents a 970.46% increase from the latest reported closing price of $6.67.
see us corporate leaderboard Maximum price target upwards.
Arcadia Biosciences has projected annual revenue of $12 million, an increase of 20.89%. Projected annual non-GAAP EPS
-$0.65.
What are other shareholders doing?
vitalstone financial
You own 0,000 shares representing 0.00% ownership of the company.
Geode Capital Management
It holds 177,000 shares representing a 20.70% ownership interest in the company. In previous filings, the company reported that it owned 178,000 of his shares.
Decrease
0.29%.office
decreased
Portfolio allocation at RKDA increased by 52.25% last quarter.
state street
It holds 102K shares representing 11.87% ownership of the company. No change from the previous quarter.
Harbor Investments
You own 0,000 shares representing 0.00% ownership of the company. No change from the previous quarter.
FNCMX – Fidelity Nasdaq Composite Index Fund
It holds 4K shares representing a 0.43% ownership interest in the company. No change from the previous quarter.
What is Fund Sentiment?
there is 38 funds or institutions reporting positions at Arcadia Biosciences. That’s an increase of his three owners or 8.57% in the last quarter.Portfolio average weight of all funds RKDA exclusive is 0.00%, a decrease of 50.36%. The total number of shares owned by the institution decreased by 27.89% to 2,370,000 shares over the past three months.
of put/call ratio has an RKDA of 0.00, indicating a bullish outlook.
Arcadia Bioscience Background Information(This description is provided by the company.)
Arcadia Biosciences is a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients. The company’s GoodWheat™ brand of ingredients deliver health benefits to consumers and enable consumer goods companies to differentiate their brands in the marketplace. The company’s GoodHemp™ seed catalog offers genetically superior hemp seeds, explants and extracts, and applies the company’s proprietary crop innovation technology, ArcaTech™, to new crops.
See all Arcadia Biosciences Submissions to regulatory authorities.
This story was originally Fintel.
The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Nasdaq, Inc.
https://www.nasdaq.com/articles/hc-wainwright-co.-maintains-arcadia-biosciences-rkda-buy-recommendation HC Wainwright & Co. Maintains Arcadia Biosciences (RKDA) Purchase Recommendation